ID   M308
AC   CVCL_D766
DR   cancercelllines; CVCL_D766
DR   Cosmic; 1425347
DR   Cosmic; 1459666
DR   Cosmic; 1665021
DR   Wikidata; Q54903592
RX   PubMed=20406486;
RX   PubMed=20689758;
RX   PubMed=22515704;
RX   PubMed=24735930;
RX   PubMed=28196595;
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: 35.0 hours (PubMed=20406486).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous (PubMed=20406486).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20406486).
CC   Omics: Protein expression by reverse-phase protein arrays.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 14
//
RX   PubMed=20406486; DOI=10.1186/1479-5876-8-39;
RA   Sondergaard J.N., Nazarian R., Wang Q., Guo D.-L., Hsueh T., Mok S.,
RA   Sazegar H., MacConaill L.E., Barretina J.G., Kehoe S.M., Attar N.,
RA   von Euw E.M., Zuckerman J.E., Chmielowski B., Comin-Anduix B.,
RA   Koya R.C., Mischel P.S., Lo R.S., Ribas A.;
RT   "Differential sensitivity of melanoma cell lines with BRAFV600E
RT   mutation to the specific Raf inhibitor PLX4032.";
RL   J. Transl. Med. 8:39.1-39.11(2010).
//
RX   PubMed=20689758; DOI=10.1593/neo.10414;
RA   Tap W.D., Gong K.-W., Dering J., Tseng Y., Ginther C., Pauletti G.,
RA   Glaspy J.A., Essner R., Bollag G., Hirth P., Zhang C., Slamon D.J.;
RT   "Pharmacodynamic characterization of the efficacy signals due to
RT   selective BRAF inhibition with PLX4032 in malignant melanoma.";
RL   Neoplasia 12:637-649(2010).
//
RX   PubMed=22515704; DOI=10.1186/1476-4598-11-22;
RA   von Euw E.M., Atefi M., Attar N., Chu C., Zachariah S., Burgess B.L.,
RA   Mok S., Ng C., Wong D.J.L., Chmielowski B., Lichter D.I., Koya R.C.,
RA   McCannel T.A., Izmailova E., Ribas A.;
RT   "Antitumor effects of the investigational selective MEK inhibitor
RT   TAK733 against cutaneous and uveal melanoma cell lines.";
RL   Mol. Cancer 11:22.1-22.9(2012).
//
RX   PubMed=24735930; DOI=10.1186/1476-4598-13-83;
RA   Lassen A., Atefi M., Robert L., Wong D.J.L., Cerniglia M.,
RA   Comin-Anduix B., Ribas A.;
RT   "Effects of AKT inhibitor therapy in response and resistance to BRAF
RT   inhibition in melanoma.";
RL   Mol. Cancer 13:83.1-83.14(2014).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//